{
    "Trade/Device Name(s)": [
        "VITEK 2 AST-Gram Negative Omadacycline",
        "VITEK 2 AST-GN Omadacycline"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K213931",
    "Predicate Device Reference 510(k) Number(s)": [
        "K191766"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON",
        "LTW",
        "LTT"
    ],
    "Summary Letter Date": "December 15, 2021",
    "Summary Letter Received Date": "December 16, 2021",
    "Submission Date": "July 25, 2021",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Omadacycline"
    ],
    "Specimen Type(s)": [
        "Bacterial or yeast isolate"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VITEK 2 System",
        "VITEK 2 Compact System"
    ],
    "Method(s)/Technology(ies)": [
        "Automated quantitative antimicrobial susceptibility test",
        "Microdilution minimum inhibitory concentration (MIC)"
    ],
    "Methodologies": [
        "Microdilution",
        "Automated susceptibility testing"
    ],
    "Submission Type(s)": [
        "Test",
        "Reagent",
        "Card"
    ],
    "Document Summary": "FDA 510(k) summary for VITEK 2 AST-Gram Negative Omadacycline antimicrobial susceptibility testing card using microdilution methodology for Gram negative bacilli.",
    "Indications for Use Summary": "Aids in determining in vitro susceptibility of Gram negative bacilli, including Enterobacter cloacae and Klebsiella pneumoniae, to Omadacycline for ABSSSI and CABP, when used with VITEK 2 systems in clinical laboratories.",
    "fda_folder": "Microbiology"
}